Updated:
NEONC Technologies Holdings
NEONC Technologies is developing intranasal perillyl alcohol targeting glioblastoma, with a Phase 1/2 trial completed for the NEO100 asset.
NEONC Technologies Holdings
NEONC Technologies Holdings, Inc. is a clinical-stage biopharmaceutical company formed to advance a portfolio of therapies for primary and secondary brain cancers, with a lead program centered on NEO100, a highly purified form of perillyl alcohol administered intranasally. The company's origin traces to research at the University of Southern California; its foundational patent estate was developed by Dr. Thomas Chen, who served as the company's scientific founder. NEONC has operated largely through equity financing and signals a development-stage posture, not a commercial one. NEONC's core mechanism of action relies on intranasal delivery to bypass the blood-brain barrier, a structural obstacle that prevents most systemic chemotherapies from reaching intracranial tumors. Its lead asset, NEO100, has completed a Phase 1/2 clinical trial for patients with recurrent glioblastoma. The company has explored additional indications for NEO100 that include leptomeningeal carcinomatosis and other central nervous system malignancies. Beyond NEO100, the pipeline references a second-generation molecule, NEO200, although publicly available data on that asset is limited. The company's geographic focus is the United States clinical trial and regulatory pathway. The firm's public disclosures signal a lean operational structure with no disclosed deployment figures or institutional product vehicles. Its public filings from the period 2015-2020 consistently described the entity as a development-stage enterprise. Clinical data posted through June 2018 reported a median overall survival of approximately 15 months in recurrent glioblastoma patients under the NEO100 regimen, per the company's own clinical trial communications. The company also conducted its initial public offering process and listed on the OTC markets. NEONC's structural differentiator is its sole reliance on the intranasal perillyl alcohol mechanism as a monotherapy targeting a niche — chemorefractory brain tumors — where the large-pharma standard of care (temozolomide, Avastin) offers limited efficacy after recurrence. The company does not report a multi-asset platform or revenue-generating diagnostics division, making it a pure clinical-trial execution play. Its corporate filings and communications have been intermittent, a posture consistent with an extremely thinly capitalized microcap.
General information
Firm type
Unclassified
Year founded
—
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Los Angeles
Corporate office
Los Angeles, CA, United States
Sector focus
Frequently asked questions
What is NEONC Technologies' lead drug candidate and its mechanism?
The lead candidate is NEO100, a highly purified form of perillyl alcohol formulated for intranasal administration. The mechanism is designed to bypass the blood-brain barrier, a physical and biochemical defense that prevents most systemic agents from reaching intracranial tumors. Pre-clinical and early clinical work suggested that the inhaled route permits direct transit to the central nervous system via the olfactory epithelium.
What clinical data has NEONC Technologies publicly released?
The company has communicated results from a Phase 1/2 clinical trial evaluating NEO100 in patients with recurrent glioblastoma. As of mid-2018, reported median overall survival for patients receiving the NEO100 regimen was approximately 15 months, per the company's clinical trial updates. Durability of response and long-term safety beyond that data window have not been comprehensively updated in public channels.
Who founded NEONC Technologies and where does the underlying intellectual property come from?
The foundational intellectual property traces to research led by Dr. Thomas Chen at the University of Southern California. Dr. Chen is credited as the scientific founder of the company and is a named inventor on key patents covering the intranasal delivery of monoterpenes, including perillyl alcohol, for targeting malignant gliomas.
What is NEONC Technologies' current operational and regulatory status?
NEONC Technologies remains a clinical-stage, development-phase entity and has not announced a commercial drug approval from the FDA. Its public filings have historically described the company as an enterprise with no recurring product revenue. Recent disclosure frequency has been low, and current management or board composition is not publicly refreshed through the firm's primary website or recent SEC filings.
How is NEONC Technologies funded, and does it maintain a family office or institutional investment vehicle structure?
The company has historically accessed capital through equity markets and is not structured as a single-family office, multi-family office, endowment, or institutional asset manager. There is no disclosed or estimated assets-under-management figure because the entity is an operating biotech issuer, not a pooled investment vehicle.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on investors?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: